About Trimax Bio sciences
Trimax Bio sciences is a company based in Raichur (India) founded in 2011 by K Jagadeeswari and Nageswara Rao was acquired by Sigachi in August 2023. Trimax Bio sciences has raised $590.9 thousand across 2 funding rounds from investors including Sigachi, Srinivasulu Devabattini and Nimmagadda Venkateswarlu. The company has 113 employees as of March 30, 2024. Trimax Bio sciences operates in a competitive market with competitors including Viyash, Inventys, Blue Jet Healthcare, Ami organics and Aparna Pharmaceuticals, among others.
- Headquarter Raichur, India
- Employees 113 as on 30 Mar, 2024
- Founders K Jagadeeswari, Nageswara Rao
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Trimax Bio Sciences Private Limited
- Date of Incorporation 11 May, 2010
- Jurisdiction Tirumalagiri, Telangana, India
-
Annual Revenue
$4.55 M (USD)-29.18as on Mar 31, 2023
-
Net Profit
-$144.53 K (USD)-123.01as on Mar 31, 2023
-
EBITDA
$206.33 K (USD)-79.3as on Mar 31, 2023
-
Total Equity Funding
$590.9 K (USD)
in 2 rounds
-
Latest Funding Round
$575.64 K (USD), Angel Round
Jan 07, 2019
-
Investors
Sigachi
& 10 more
-
Employee Count
113
as on Mar 30, 2024
-
Acquired by
Sigachi
(Aug 10, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Trimax Bio sciences
Trimax Bio sciences has successfully raised a total of $590.9K across 2 strategic funding rounds. The most recent funding activity was a Angel Round of $575.64 thousand completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Angel Round — $575,636
-
First Round
First Round
(20 Mar 2017)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2019 | Amount | Angel Round - Trimax Bio sciences | Valuation | Srinivasulu Devabattini | |
| Mar, 2017 | Amount | Angel Round - Trimax Bio sciences | Valuation | A Shiva Lakshmi |
|
Investors in Trimax Bio sciences
Trimax Bio sciences has secured backing from 11 investors, including angel investors. Prominent investors backing the company include Sigachi, Srinivasulu Devabattini and Nimmagadda Venkateswarlu.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
SD
Srinivasulu Devabattini |
-
|
Founded Year | Domain | Location |
|
NV
Nimmagadda Venkateswarlu |
-
|
Founded Year | Domain | Location |
|
NP
Nimmagadda Padmavathi |
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Trimax Bio sciences
Financial Statements - Trimax Bio sciences
Trimax Bio Sciences Comparisons
Competitors of Trimax Bio sciences
Trimax Bio sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viyash, Inventys, Blue Jet Healthcare, Ami organics and Aparna Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
APIs and intermediates are manufactured by Viyash as a CDMO.
|
|
| domain | founded_year | HQ Location |
Actives, advanced intermediates, and specialty chemicals are custom manufactured.
|
|
| domain | founded_year | HQ Location |
CDMO focused on manufacturing, supplier, and development of intermediates & APIs
|
|
| domain | founded_year | HQ Location |
Advanced API intermediates are manufactured for pharmaceutical use.
|
|
| domain | founded_year | HQ Location |
API intermediates are manufactured by Aparna Pharmaceuticals as a CDMO.
|
|
| domain | founded_year | HQ Location |
CDMO focused on manufacturing of APIs and intermediates
|
Latest news on Trimax Bio Sciences
Frequently Asked Questions about Trimax Bio sciences
Trimax Bio sciences was founded in 2011 and raised its 1st funding round 6 years after it was founded.
Trimax Bio sciences is headquartered in Raichur, India. It is registered at Raichur, Karnataka, India.
Trimax Bio sciences is a funded company, having raised a total of $590.9K across 2 funding rounds to date. The company's 1st funding round was a Angel Round of $15.26K, raised on Mar 20, 2017.
As of Mar 30, 2024, the latest employee count at Trimax Bio sciences is 113.
Annual revenue of Trimax Bio sciences is $4.55M as on Mar 31, 2023.
Trimax Bio sciences was established in 2011 in Raichur, India, within the pharmaceutical sector. Research on non-infringing processes is conducted, alongside manufacturing of various healthcare intermediates. Products such as metformin, pregabalin, dimethylphenoxyacetic acid, and pantoprazole sodium sesquihydrate are produced to support broader pharmaceutical applications. Operations remain centered on these core activities in the Indian market.
Trimax Bio sciences's top competitors include Inventys, Viyash and Blue Jet Healthcare.
Trimax Bio sciences has 11 investors. Key investors include Sigachi, Srinivasulu Devabattini, Nimmagadda Venkateswarlu, Nimmagadda Padmavathi, and Hema Latha Devabathini.
The valuation of Trimax Bio sciences is $9.23M as of Jan 2019.